RxDoctor Payments Data

Stephen Regan, MD

Internal Medicine · Plymouth, NHNPI 1336127000

Payments from drug & device makers

$475in general payments, 2019–2025

Across 26 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$144
  • Novo Nordisk$102
  • AstraZeneca$81
  • Sanofi$33
  • Amgen$29
  • GSK$28
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie8$144
Novo Nordisk6$102
AstraZeneca4$81
Sanofi1$33
Amgen2$29
GSK2$28
Sanofi Pasteur Inc.1$25
Pfizer1$17
Amarin Pharma, Inc.1$16

How this compares

$475 in reported general payments places this provider in the 85th percentile of 504 internal medicine providers in New Hampshire.

See all internal medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$2,183
Medicare patients
36
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol50$50,932
OzempicSemaglutide41$49,230
EliquisApixaban35$48,458
JardianceEmpagliflozin39$44,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$30,211
MounjaroTirzepatide26$28,132
JanuviaSitagliptin Phosphate22$25,448
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$9,325
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$6,384
Breo ElliptaFluticasone/Vilanterol13$5,072
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,879
Atorvastatin Calcium282$2,629
Pregabalin25$2,393
Omeprazole116$1,917
Albuterol Sulfate HfaAlbuterol Sulfate59$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$81$50,93250 claims
Novo NordiskOzempic$102$49,23041 claims
PfizerEliquis$17$48,45835 claims
GSKTrelegy Ellipta, Breo Ellipta$28$35,28243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 504 internal medicine providers in New Hampshire.

Other internal medicine in Plymouth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →